Organization
Cyclacel Pharmaceuticals
8 clinical trials
Clinical trial
A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CYC140, an Oral PLK1 Inhibitor, in Subjects With Advanced Solid Tumors and LymphomaStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-CYC065 Following a Single Oral Dose in Healthy Male SubjectsStatus: Active (not recruiting), Estimated PCD: 2023-03-04
Clinical trial
A Phase I Combination Study of CYC065 and Venetoclax in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromesStatus: Completed, Estimated PCD: 2022-11-15
Clinical trial
A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects With Advanced Solid Tumors and LymphomaStatus: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
A Phase 1/2, Open Label, Multicenter Study to Investigate the Safety and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects With Leukemias or Myelodysplastic Syndrome (MDS)Status: , Estimated PCD: 2024-10-01
Clinical trial
A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Status: Completed, Estimated PCD: 2022-11-15
Clinical trial
A Phase I Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced CancersStatus: Completed, Estimated PCD: 2022-10-04
Clinical trial
A Randomized Phase 2 Study of Oral Sapacitabine in Elderly Patients With Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic SyndromesStatus: Completed, Estimated PCD: 2018-12-01